|
2024-01-31 |
2024-01-29 |
VP
Vente planifiée
|
Vasquez Nicki
CHIEF PORT. STRAT & ALNCE OFCR
Dirigeant
|
12 185
-48.8%
5,00
60 925 USD
|
12 185
-48.8%
|
5,00
|
60 925 USD
|
|
|
2023-08-29 |
2023-08-28 |
VP
Vente planifiée
|
Shtylla Brunilda
Chief Business Officer
Dirigeant
|
15 428
-100.0%
4,71
72 595 USD
|
15 428
-100.0%
|
4,71
|
72 595 USD
|
|
|
2023-08-28 |
2023-08-25 |
V
Vente
|
Shtylla Brunilda
Chief Business Officer
Dirigeant
|
11 613
-47.3%
4,59
53 282 USD
|
11 613
-47.3%
|
4,59
|
53 282 USD
|
|
|
2022-03-15 |
2022-03-14 |
A
Achat
|
NEWELL WILLIAM J
CEO
Administrateur exécutif
|
10 000
+9.4%
7,75
77 508 USD
|
10 000
+9.4%
|
7,75
|
77 508 USD
|
|
|
2021-09-28 |
2021-09-28 |
VP
Vente planifiée
|
Vasquez Nicki
Chief Port. Strat & Alnce Ofcr
Dirigeant
|
3 906
-34.9%
18,62
72 724 USD
|
3 906
-34.9%
|
18,62
|
72 724 USD
|
|
|
2021-01-27 |
2021-01-26 |
VP
Vente planifiée
|
Hallam Trevor
Chief Scientific Officer
Dirigeant
|
165
-0.3%
26,10
4 306 USD
|
165
-0.3%
|
26,10
|
4 306 USD
|
|
|
2021-01-27 |
2021-01-26 |
VP
Vente planifiée
|
Hallam Trevor
Chief Scientific Officer
Dirigeant
|
2 228
-3.8%
25,68
57 222 USD
|
2 228
-3.8%
|
25,68
|
57 222 USD
|
|
|
2020-12-29 |
2020-12-28 |
VP
Vente planifiée
|
Hallam Trevor
Chief Scientific Officer
Dirigeant
|
2 393
-6.1%
22,37
53 530 USD
|
2 393
-6.1%
|
22,37
|
53 530 USD
|
|
|
2020-11-30 |
2020-11-27 |
VP
Vente planifiée
|
Hallam Trevor
Chief Scientific Officer
Dirigeant
|
2 393
-6.1%
17,01
40 713 USD
|
2 393
-6.1%
|
17,01
|
40 713 USD
|
|
|
2020-11-06 |
2020-11-05 |
VP
Vente planifiée
|
Hallam Trevor
Chief Scientific Officer
Dirigeant
|
16 751
-31.3%
15,00
251 265 USD
|
16 751
-31.3%
|
15,00
|
251 265 USD
|
|
|
2020-09-28 |
2020-09-28 |
VP
Vente planifiée
|
Hallam Trevor
Chief Scientific Officer
Dirigeant
|
975
-3.4%
10,26
10 007 USD
|
975
-3.4%
|
10,26
|
10 007 USD
|
|
|
2020-09-22 |
2020-09-18 |
V
Vente
|
Freund John Gordon
Administrateur non-exécutif
|
400 000
-41.7%
12,00
4 800 000 USD
|
400 000
-41.7%
|
12,00
|
4 800 000 USD
|
|
|
2020-09-15 |
2020-09-11 |
V
Vente
|
Freund John Gordon
Administrateur non-exécutif
|
500 000
-34.2%
10,00
5 000 000 USD
|
500 000
-34.2%
|
10,00
|
5 000 000 USD
|
|
|
2020-08-27 |
2020-08-26 |
VP
Vente planifiée
|
Hallam Trevor
Chief Scientific Officer
Dirigeant
|
975
-5.5%
9,04
8 818 USD
|
975
-5.5%
|
9,04
|
8 818 USD
|
|
|
2020-08-21 |
2020-08-19 |
V
Vente
|
Freund John Gordon
Administrateur non-exécutif
|
500 000
-25.5%
8,72
4 360 000 USD
|
500 000
-25.5%
|
8,72
|
4 360 000 USD
|
|
|
2020-07-28 |
2020-07-27 |
VP
Vente planifiée
|
Hallam Trevor
Chief Science Officer
Dirigeant
|
975
-5.2%
8,06
7 858 USD
|
975
-5.2%
|
8,06
|
7 858 USD
|
|
|
2020-05-27 |
2020-05-26 |
VP
Vente planifiée
|
Hallam Trevor
Chief Science Officer
Dirigeant
|
975
-4.7%
10,00
9 753 USD
|
975
-4.7%
|
10,00
|
9 753 USD
|
|
|
2020-05-14 |
2020-05-14 |
A
Achat
|
NEWELL WILLIAM J
CEO
Administrateur exécutif
|
64 516
+63.2%
7,75
499 999 USD
|
64 516
+63.2%
|
7,75
|
499 999 USD
|
|
|
2020-05-14 |
2020-05-14 |
A
Achat
|
MOLINA ARTURO MD
Chief Medical Officer
Dirigeant
|
6 451
+114.5%
7,75
49 995 USD
|
6 451
+114.5%
|
7,75
|
49 995 USD
|
|
|
2020-05-14 |
2020-05-14 |
A
Achat
|
FITZPATRICK LINDA A
Chief People & Comm. Officer
Dirigeant
|
3 225
+55.8%
7,75
24 994 USD
|
3 225
+55.8%
|
7,75
|
24 994 USD
|
|
|
2020-04-27 |
2020-04-27 |
VP
Vente planifiée
|
Hallam Trevor
Chief Science Officer
Dirigeant
|
2
-0.0%
11,19
22 USD
|
2
-0.0%
|
11,19
|
22 USD
|
|
|
2020-04-27 |
2020-04-27 |
VP
Vente planifiée
|
Hallam Trevor
Chief Science Officer
Dirigeant
|
973
-4.5%
9,41
9 161 USD
|
973
-4.5%
|
9,41
|
9 161 USD
|
|
|
2020-03-27 |
2020-03-26 |
VP
Vente planifiée
|
Hallam Trevor
Chief Science Officer
Dirigeant
|
975
-4.3%
9,69
9 453 USD
|
975
-4.3%
|
9,69
|
9 453 USD
|
|
|
2020-02-27 |
2020-02-26 |
VP
Vente planifiée
|
Hallam Trevor
Chief Science Officer
Dirigeant
|
975
-4.1%
10,47
10 207 USD
|
975
-4.1%
|
10,47
|
10 207 USD
|
|
|
2020-01-28 |
2020-01-27 |
VP
Vente planifiée
|
Hallam Trevor
Chief Science Officer
|
975
-4.0%
10,51
10 250 USD
|
975
-4.0%
|
10,51
|
10 250 USD
|
|
|
2019-12-27 |
2019-12-26 |
VP
Vente planifiée
|
Hallam Trevor
Chief Science Officer
Dirigeant
|
975
-3.8%
11,08
10 802 USD
|
975
-3.8%
|
11,08
|
10 802 USD
|
|
|
2019-11-27 |
2019-11-26 |
VP
Vente planifiée
|
Hallam Trevor
Chief Science Officer
|
975
-3.7%
10,68
10 410 USD
|
975
-3.7%
|
10,68
|
10 410 USD
|
|
|
2019-10-30 |
2019-10-28 |
VP
Vente planifiée
|
Hallam Trevor
Chief Science Officer
|
975
-3.5%
9,98
9 726 USD
|
975
-3.5%
|
9,98
|
9 726 USD
|
|
|
2018-10-02 |
2018-10-01 |
A
Achat
|
Merck & Co., Inc.
Actionnaire important
|
666 666
+32.4%
15,00
9 999 990 USD
|
666 666
+32.4%
|
15,00
|
9 999 990 USD
|
|
|
2018-10-01 |
2018-10-01 |
V
Vente
|
Petree Daniel H
Administrateur non-exécutif
|
122
-38.9%
15,00
1 830 USD
|
122
-38.9%
|
15,00
|
1 830 USD
|
|
